Immunome Inc
IMNM
Company Profile
Business description
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Contact
18702 N. Creek Parkway
Suite 100
BothellWA98011
USAT: +1 425 939-7410
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
131
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,777.30 | 2.50 | 0.03% |
| CAC 40 | 7,615.99 | 78.42 | 1.04% |
| DAX 40 | 23,641.58 | 372.57 | 1.60% |
| Dow JONES (US) | 43,089.02 | 507.24 | 1.19% |
| FTSE 100 | 8,758.99 | 0.95 | 0.01% |
| HKSE | 24,362.73 | 185.66 | 0.77% |
| NASDAQ | 19,912.53 | 281.56 | 1.43% |
| Nikkei 225 | 38,856.14 | 65.58 | 0.17% |
| NZX 50 Index | 12,448.64 | 18.84 | -0.15% |
| S&P 500 | 6,092.18 | 67.01 | 1.11% |
| S&P/ASX 200 | 8,557.00 | 1.50 | 0.02% |
| SSE Composite Index | 3,430.16 | 9.60 | 0.28% |